REG - Oxford BioDynamics - PDMR Dealing / Grant of Share Options

Oxford BiodynamicsAnnouncement

03/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250303:nRSC0022Za&default-theme=true

RNS Number : 0022Z  Oxford BioDynamics PLC  03 March 2025

 

 

3 March
2025

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD, the Company),  a precision clinical
diagnostics company bringing specific and sensitive tests to the practice of
medicine based on its EpiSwitch® 3D genomics platform, announces that it has
today granted a total of 218,000,000 options over its ordinary shares of 0.1
pence each ("Ordinary Shares"), to Group employees and advisers, including
certain directors and PDMRs of the Company, as outlined in the table below.

The options were granted under the Company's 2016 Employee and Non-Employee
Share Option Plans with an exercise price of 0.55p per share, being the
closing share price on 28 February 2025, the business day immediately
preceding the grant of the options. Prior to the grant, Chief Financial
Officer Paul Stockdale surrendered 70,000 share options originally awarded in
2018.

96,000,000 options have been award to Executive Chairman Iain Ross; 4,000,000
of these options will vest immediately and the remaining 92,000,000 options
will vest in 23 equal instalments on the final day of each month to January
2027. All other newly-granted options will vest in three equal tranches on the
first, second and third anniversaries of the date of grant. Vested options
will remain exercisable up to and including the tenth anniversary of the date
of grant.

Following this grant, the individuals referred to above hold options over
Ordinary Shares and are interested in Ordinary Shares as follows:

                                                  New options granted  Total number of options over Ordinary Shares  Ordinary Shares held
                                                  Number                                                             % of current issued share capital
 Iain Ross, Executive Chairman                    96,000,000           96,000,000                                    10,000,000                         0.51
 Alexandre Akoulitchev, Chief Scientific Officer  18,000,000           19,596,131                                    7,562,296                          0.39
 David Blum, SVP of Marketing                     18,000,000           18,462,500                                    744,611                            0.04
 Thomas Guiel, Chief Operations Officer           18,000,000           18,650,000                                    1,288,146                          0.07
 Ewan Hunter, Chief Data Officer                  18,000,000           18,660,000                                    722,754                            0.04
 Paul Stockdale, Chief Financial Officer          18,000,000           18,980,000                                    3,077,919                          0.16

 

The notifications below, made in accordance with the requirements of UK Market
Abuse Regulation, provide further details:

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Alexandre Akoulitchev
 2   Reason for the notification
 a)  Position/status                                              Director/PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Grant of share options
 c)  Price(s) and volume(s)                                       18,000,000 ordinary shares at an exercise price of 0.55 pence per share

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      3 March 2025

 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         David Blum
 2   Reason for the notification
 a)  Position/status                                              PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Grant of share options
 c)  Price(s) and volume(s)                                       18,000,000 ordinary shares at an exercise price of 0.55 pence per share

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      3 March 2025

 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Thomas Guiel
 2   Reason for the notification
 a)  Position/status                                              PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Grant of share options
 c)  Price(s) and volume(s)                                       18,000,000 ordinary shares at an exercise price of 0.55 pence per share

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      3 March 2025

 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Ewan Hunter
 2   Reason for the notification
 a)  Position/status                                              PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Grant of share options
 c)  Price(s) and volume(s)                                       18,000,000 ordinary shares at an exercise price of 0.55 pence per share

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      3 March 2025

 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Iain Ross
 2   Reason for the notification
 a)  Position/status                                              Director/PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Grant of share options
 c)  Price(s) and volume(s)                                       96,000,000 ordinary shares at an exercise price of 0.55 pence per share

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      3 March 2025

 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Paul Stockdale
 2   Reason for the notification
 a)  Position/status                                              Director/PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Surrender and grant of share options
 c)  Price(s) and volume(s)                                       Options over 70,000 ordinary shares at an exercise price of £1.70 per share
                                                                  cancelled

                                                                  Options over 18,000,000 ordinary shares at an exercise price of 0.55 pence per
                                                                  share granted

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Dates of the transactions                                    28 February, 3 March 2025

 f)  Place of the transaction                                     Outside a trading venue

 

 

 

-Ends-

For further details please contact:

  Oxford BioDynamics Plc                                              Tel: +44 (0)1865 518910
 Iain Ross Executive Chairman

 Paul Stockdale, CFO
 Shore Capital - Nominated Adviser and Broker                         Tel: +44 (0)20 7408 4090
 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy
 OAK Securities - Joint Broker                                        Tel: +44 (0)20 3973 3678
 Jerry Keen / Henry Clarke / Damion Carruel
 WG Partners - Joint Broker                                           Tel: +44 (0)20 3705 9330
 David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
 Camarco - Financial PR                                               Tel: +44 (0)20 3757 4980
 Marc Cohen / Tilly Butcher / Fergus Young                            OBDFinancial@camarco.co.uk

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKLLFBEXLFBBQ